Fliser D, Lorenzo MM, Houghton K, Ainsworth C, Blogg M, Gonzalez de Antona Sanchez E, Portles J. Real-life anemia management among patients with non-dialysis-dependent chronic kidney disease in three European countries. Int J Nephrol Renovasc Dis. 2023 Apr 13;16:115-29. doi: 10.2147/IJNRD.S401598
Zhou X, Garbinsky D, Ouyang J, Davenport E, Agarwal I, Oberdhan D. Longitudinal data on treatment duration and compliance from autosomal dominant polycystic kidney disease clinical trials with tolvaptan. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa139.S. doi: 10.1093/ndt/gfaa139.SO093
Zhou X, Davenport E, Ouyang J, Hoke M, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across an expanded pooled database of multiple autosomal dominant polycystic kidney disease clinical studies. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa142.P. doi: 10.1093/ndt/gfaa142.P0037
Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019 Aug;44(4):495-507. doi: 10.1111/jcpt.12830
Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012 Dec 1;5:151-63.
Goyal RK, Rajan SS, Essien EJ, Sansgiry SS. Effectiveness of FDA's new over-the-counter acetaminophen label warning requirements in improving consumer risk perception of liver damage. J Clin Pharm Ther. 2012 Dec;37(6):681-5. doi: 10.1111/j.1365-2710.2012.01371.x.